Vertex
POSTED
04-10-23
2022 Represented a Strategic Inflection Point for Vertex and Its Core Mission of Creating Transformative Medicines for People With Serious Diseases; Announces 2022 Corporate Responsibility Report
2022 represented a strategic inflection point for Vertex and its core mission of investing in scientific innovation to create transformative medicines for people with serious diseases.
POSTED
04-11-22
In an Extraordinary Year, Vertex Continues Its Unwavering Commitment to Corporate Responsibility; Announces 2021 CR Report
2021 was an important year for Vertex and one that positioned the company well for the future as they continued to discover, develop and commercialize transformative medicines for people with serious diseases while demonstrating an unwavering commitment to corporate responsibility.
POSTED
04-13-21
In a Remarkable Year, Vertex Fuels Its Efforts in Corporate Responsibility; Announces 2020 CR Report
The COVID-19 pandemic and a heightened focus on social and racial justice brought about unprecedented disruption, change and uncertainty. Yet during such a time, Vertex remained steadfast in its mission to innovate and deliver transformative medicines and remained equally committed to supporting ...
POSTED
05-19-20
Vertex Publishes 2019 Corporate Responsibility Report
May 19, 2020 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, announces its 2019 Corporate Responsibility report.
This
